Scicom J Med Appl Med Sci
& Hirschmann, R
Disclosures: Taotao Yan: Nothing to Disclose, Nicholas Chien: Nothing to Disclose, Ashley Fong: Nothing to Disclose, Vy Nguyen: Nothing to Disclose, Isaac Le: Nothing to Disclose, Annie Fung: Nothing to Disclose, Surya Teja Gudapati: Nothing to Disclose, Sally Tran: Nothing to Disclose, Angela Chau: Nothing to Disclose, Xinrong Zhang: Nothing to Disclose, Jung Eun Park: Nothing to Disclose, Ramsey Cheung: Nothing to Disclose, Changqing Zhao: Nothing to Disclose, Mingjuan Jin: Nothing to Disclose 1181 SUBOPTIMAL DIAGNOSIS RATE AND PERI-COMPLICATION DIAGNOSIS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN THE U.S.: A POPULATION-BASED STUDY Vy Nguyen 1 Scott Barnett 1 Xinrong Zhang 1 Ramsey Cheung 2 Mindie Nguyen 2 , 1 Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA, 2 Stanford University Medical Center Background: The incidence of MASLD is estimated to affect over half of the global adult population by 2040, yet disease awareness remains low in the U.S
ATMC recognizes this potential risk and treats it with safe and gentle neurotoxin removal techniques
